Jun 2026 (Q2 FY26) — Aug 13, 2026
HeartFlow Q2 FY26 — Strong Revenue Growth Driven by Plaque and FFRCT Momentum, Full-Year Outlook Raised
Read the full callHeartFlow (HTFL) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
HeartFlow earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 64.1 | +47.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -27.9 | +3.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -15.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$51.02 +5.65% · +$2.73
Performance +51.1% 1Y
1Y: $33.77 on 17 Oct 2025 → $51.02. High $52.21 (5 Oct 2026), low $20.49 (13 Mar 2026).
- Previous close
- $48.29
- 52-week range
- $20.49 – $52.21
- One year
- +45.56%
Overview
- Symbol
- HTFL
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
HeartFlow earnings calls (HTFL)
Financials
What the filings say
Net profit, year on year: −71% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 33 | 35 | 37 | 43 | 46 | 49 | 53 | 64 |
| Operating profit | -15 | -16 | -18 | -14 | -15 | -18 | -30 | -18 |
| Operating margin | −45.3% | −45.9% | −47.0% | −31.6% | −32.6% | −36.1% | −56.1% | −27.9% |
| Other income | — | — | -15 | 5 | — | — | 2 | 2 |
| Interest | 5 | 5 | 5 | 7 | 3 | 0 | 0 | — |
| Profit before tax | -19 | -33 | -32 | -9 | -51 | -25 | -27 | -16 |
| Tax rate | 0.0% | −0.0% | — | −0.7% | −0.1% | 0.7% | −0.1% | −0.1% |
| Net profit | -19 | -33 | -32 | -9 | -51 | -24 | -27 | -16 |
| EPS ($ per share) | -3.43 | — | -5.25 | -1.46 | -1.04 | — | -0.32 | -0.18 |
| Line item | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Equity capital | — | 0 | 0 |
| Reserves | -1 | -971 | -1,088 |
| Total liabilities | — | 210 | 59 |
| Fixed assets | — | 9 | 9 |
| Investments | — | — | 132 |
| Total assets | — | 119 | 359 |
| Line item | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Cash from operations | -76 | -69 | -54 |
| Cash from investing | -6 | -4 | -239 |
| Cash from financing | 169 | 2 | 286 |
| Net cash flow | 86 | -71 | -6 |
| Capital expenditure | -6 | -4 | -5 |
| Free cash flow | -83 | -73 | -59 |
HTFL revenue by segment
| Segment | Q2 FY2025 | Q3 FY2025 | YoY growth latest quarter |
|---|---|---|---|
| Non Invasive CAD Detection Solutions | 100% | 100% | — |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- Non Us 6%
As HTFL cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
99 filings between Nov 7, 2025 and Oct 12, 2026.
Open market
decisions to buy or sellPurchases
$1.05M
1 purchase by 1 insider
Sales
$140.00M
37 sales by 5 insiders
86% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 7
- Award — granted as compensation
- 28
- Option exercise — converted options into shares
- 24
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 other filings.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | — | $115.00M | Apr 30, 2026 |
| Farquhar John C.M. | — | $12.87M | Oct 12, 2026 |
| Rogers Campbell | — | $6.71M | Sep 18, 2026 |
| Verghese Vikram | — | $4.98M | Sep 18, 2026 |
| Lightcap Jeffrey C | $1.05M | — | Dec 16, 2025 |
| Cullivan Julie A | — | $446.6K | Mar 5, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 12, 2026 | Farquhar John C.M. Chief Executive Officer | Sale 10b5-1 plan | 38,900 | $1.93M |
| Sep 18, 2026 | Rogers Campbell Chief Medical Officer | Sale 10b5-1 plan | 19,682 | $987.1K |
| Sep 18, 2026 | Rogers Campbell Chief Medical Officer | Option exercise 10b5-1 plan | 850 | $1.9K |
| Sep 18, 2026 | Rogers Campbell Chief Medical Officer | Option exercise 10b5-1 plan | 12,329 | $102.7K |
| Sep 18, 2026 | Verghese Vikram Chief Financial Officer | Sale 10b5-1 plan | 16,766 | $850.9K |
| Sep 17, 2026 | Verghese Vikram Chief Financial Officer | Sale 10b5-1 plan | 7,579 | $379.8K |
| Sep 15, 2026 | Verghese Vikram Chief Financial Officer | Sale 10b5-1 plan | 668 | $33.4K |
| Sep 14, 2026 | Verghese Vikram Chief Financial Officer | Sale 10b5-1 plan | 4,593 | $230.7K |
| Sep 11, 2026 | Verghese Vikram Chief Financial Officer | Sale 10b5-1 plan | 29,714 | $1.49M |
| Sep 11, 2026 | Farquhar John C.M. Chief Executive Officer | Sale 10b5-1 plan | 3,890 | $194.5K |
| Sep 10, 2026 | Farquhar John C.M. Chief Executive Officer | Sale 10b5-1 plan | 35,010 | $1.63M |
| Sep 8, 2026 | Verghese Vikram Chief Financial Officer | Sale 10b5-1 plan | 6,640 | $332.2K |
| Sep 3, 2026 | Verghese Vikram Chief Financial Officer | Sale 10b5-1 plan | 27,540 | $1.37M |
| Sep 2, 2026 | Verghese Vikram Chief Financial Officer | Sale 10b5-1 plan | 5,876 | $297.3K |
| Aug 21, 2026 | Farquhar John C.M. Chief Executive Officer | Sale 10b5-1 plan | 27,230 | $1.36M |
| Aug 18, 2026 | Farquhar John C.M. Chief Executive Officer | Sale 10b5-1 plan | 32,676 | $1.47M |
| Aug 17, 2026 | Rogers Campbell Chief Medical Officer | Sale 10b5-1 plan | 9,219 | $380.1K |
| Aug 17, 2026 | Rogers Campbell Chief Medical Officer | Option exercise 10b5-1 plan | 9,219 | $175.2K |
| Aug 14, 2026 | Farquhar John C.M. Chief Executive Officer | Sale 10b5-1 plan | 15,560 | $607.8K |
| Aug 10, 2026 | Farquhar John C.M. Chief Executive Officer | Sale 10b5-1 plan | 22,562 | $638.7K |
| Aug 7, 2026 | Verghese Vikram Chief Financial Officer | Tax withheld | 473 | $13.6K |
| Aug 7, 2026 | Rogers Campbell Chief Medical Officer | Tax withheld | 637 | $18.4K |
| Aug 7, 2026 | Jones Marie L. Chief Accounting Officer | Tax withheld | 82 | $2.4K |
| Aug 7, 2026 | Farquhar John C.M. Chief Executive Officer | Tax withheld | 1,904 | $54.9K |
| Aug 6, 2026 | Jones Marie L. Chief Accounting Officer | Tax withheld | 486 | $13.2K |
| Aug 6, 2026 | Verghese Vikram Chief Financial Officer | Tax withheld | 1,537 | $41.8K |
| Aug 6, 2026 | Rogers Campbell Chief Medical Officer | Tax withheld | 1,635 | $44.5K |
| Aug 6, 2026 | Farquhar John C.M. Chief Executive Officer | Tax withheld | 5,847 | $159.0K |
| Jul 30, 2026 | Farquhar John C.M. Chief Executive Officer | Option exercise | 2,789 | $23.2K |
| Jul 30, 2026 | Farquhar John C.M. Chief Executive Officer | Option exercise | 9,737 | $93.3K |
| Jul 30, 2026 | Farquhar John C.M. Chief Executive Officer | Option exercise | 18,694 | $41.5K |
| Jul 27, 2026 | Verghese Vikram Chief Financial Officer | Option exercise | 22,522 | $50.0K |
| Jul 24, 2026 | Lightcap Jeffrey C Director | Option exercise | 47,420 | $901.0K |
| Jul 22, 2026 | BARABE TIMOTHY C Director | Option exercise | 3,710 | $70.5K |
| Jul 21, 2026 | Verghese Vikram Chief Financial Officer | Option exercise | 22,522 | $50.0K |
| Jul 17, 2026 | BARABE TIMOTHY C Director | Option exercise | 5,000 | $95.0K |
| Jul 15, 2026 | Rogers Campbell Chief Medical Officer | Sale 10b5-1 plan | 9,219 | $237.1K |
| Jul 15, 2026 | Rogers Campbell Chief Medical Officer | Option exercise 10b5-1 plan | 9,219 | $175.2K |
| Jul 10, 2026 | Farquhar John C.M. Chief Executive Officer | Sale 10b5-1 plan | 22,562 | $626.1K |
| Jul 8, 2026 | WELDON WILLIAM C Director | Option exercise | 17,123 | $142.6K |
| Jul 8, 2026 | WELDON WILLIAM C Director | Option exercise | 17,123 | $142.6K |
| Jul 8, 2026 | WELDON WILLIAM C Director | Option exercise | 17,123 | $142.6K |
| Jun 24, 2026 | Farquhar John C.M. Chief Executive Officer | Sale 10b5-1 plan | 38,900 | $1.36M |
| Jun 15, 2026 | Rogers Campbell Chief Medical Officer | Option exercise 10b5-1 plan | 10,000 | $22.2K |
| Jun 10, 2026 | Farquhar John C.M. Chief Executive Officer | Sale 10b5-1 plan | 22,562 | $643.0K |
| May 18, 2026 | Rogers Campbell Chief Medical Officer | Option exercise 10b5-1 plan | 9,219 | $175.2K |
| May 18, 2026 | Rogers Campbell Chief Medical Officer | Sale 10b5-1 plan | 9,219 | $261.3K |
| May 11, 2026 | Farquhar John C.M. Chief Executive Officer | Sale 10b5-1 plan | 22,562 | $657.0K |
| May 7, 2026 | Jones Marie L. Chief Accounting Officer | Tax withheld | 82 | $2.5K |
| May 7, 2026 | Rogers Campbell Chief Medical Officer | Tax withheld | 637 | $19.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Heartflow, Inc.
Free account. Everything above stays public.
Write why you follow Heartflow, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading